Amendments to the Claims

Please amend the claims as set forth in the List of Claims below.

List of Claims

1.   (Currently amended) A method of determining whether a human female subject is at increased risk of having ovarian cancer relative to the general population, comprising:

    (a)   obtaining a test biological sample of urine from said subject;

    (b)   determining the amount of eosinophil-derived neurotoxin (EDN) in said test biological sample. wherein said EDN is characterized by the amino acid sequence of SEQ ID NO:1;

    (c)   comparing the amount of EDN determined in step (b) with the amount in one or more control biological samples of urine; and

    (d)   concluding that said subject ~~has or is likely to develop~~ is at increased risk of having ovarian cancer relative to the general population if the amount of EDN in said test biological sample is at least 20% higher than in said control biological samples.

2-4.   (Cancelled)

5.   (Previously presented) The method of claim 1, wherein the determination of EDN amount is accomplished using an immunoassay.

6.   (Withdrawn) The method of claim 1, wherein the amount of EDN is determined by mass spectrometry.

7.   (Withdrawn) The method of claim 1, wherein the amount of EDN is determined by surface enhanced laser desorption/ionization mass spectrometry.

8-9.   (Cancelled)

10.   (Withdrawn) The method of any one of claims 1 or 5-7, further comprising performing at least one additional assay for a diagnostic marker of cancer or other disease.

11.   (Withdrawn) The method of claim 10, wherein said diagnostic marker is selected from the group consisting of: prostate specific antigen; BRCA-1 and BRCA-2.

12.   (Withdrawn) The method of claim 10, wherein said diagnostic marker is CA 125.

13.   (Previously presented) The method of any one of claims 1 or 5-7, wherein said subject is selected for testing based upon a clinical determination that she is at an elevated risk of having or developing ovarian cancer.

14-18. (Cancelled)